Addressing Pharma’s Three Expensive ‘Achilles Heels’ Business Summary

 Pharma spent $57Bn on R&D in 2005  Pharma industry has at least three ‘Achilles Heels’:  1) identifying persons for Post-marketing Surveillance,  2) improved compliance (regularly picking up and taking prescribed meds) and  3) patient recruitment for multiple phases of clinical trials  Each of these ‘Achilles Heels’ is data-centric, which requires signed authorizations that enable access to sensitive personal information  ‘Achilles Heels’ erode precious patent life of products and require billions in spending each year, the efficiency of which is questionable Pharma’s Three ‘Achilles Heels’

Proprietary & Confidential © You Take Control, Inc. 3 We put you in control to protect your by providing you, the rightful owner, with electronic tools to selectively decide who sees it, what parts they see, and how you make money from its use sensitive personal information (which is collected and stored by others) The New World – YTC’s Consumer Mission 3

Proprietary & Confidential © You Take Control, Inc. Strategy This model is founded on acquiring millions of ‘members’ who use the company’s electronic consent tools to access and selectively control their sensitive personal information. Members are acquired through numerous channels (phone carriers at&t, Verizon, AARP with 40M Seniors, credit card companies etc.). YTC’s primary short-term strategy is to attract members through organizations with millions of constituents because both the companies and each of their subscribers get $$. Revenue is primarily member-driven (membership fees, Rx data retrieval, permission-based funded studies, pharma CROs) but will be supplemented by other consent-driven opportunities. To more quickly and efficiently identify and qualify candidates for all three issues mentioned above resulting in longer time for the drug on the market, reduced costs and more intelligent and efficient spending

Potential Sources of YTC Members 5

Proprietary & Confidential © You Take Control, Inc. 6 Market Dynamics - Summary  A range of Worldwide issues continue to plague Pharma as they search for ways to lower costs, fill pipelines, reduce time to market  Cost of drug discovery processes (e.g. yield about 8 out of 10 never make it to market) continue to rise, protracted times to market due in part to antiquated means of ‘finding qualified candidates’  Pressures mount to reduce the price of products in most lucrative markets (particularly in the U.S. vs. Canada as an example)  A near ‘ocean of generics’ make discovery processes more challenging pushing up costs, while reducing current revenues  Growing emphasis on genomic data opens up potential for vast new markets for Pharma but costs are significant  Crushing regulatory mandates to spend many $Bn on addressing post-marketing surveillance (Phase IV) studies continue to impact Pharma’s business prospects and market cap valuations 6

Proprietary & Confidential © You Take Control, Inc. Time Is Money $ Drug’s Revenue-Generating Period Year 17 Revenues from a Blockbuster Drug may be as much as $28 billion or more $400 million Profit from a Regular Drug is $400 million Pharma’s Objective: Shift the Revenue Curves to the Left Today: 12 years and >$1B to develop a FDA-approved drug Year 12 “The YTC Effect:” Reduce drug development costs from >$1B to about $800M AND shortens the time to market from 12 years to 10 Yrs or less! RESULT: $28B MORE Revenue. Bonus: Adds Two or more peak revenue years During Year 20 : Patent Expires Year 16 Year 15 YTC Enables: Launch in Year 10, NOT Year 12

Proprietary & Confidential © You Take Control, Inc. Detailed Strategy Secure access to Rx data and members via organizations with large numbers of constituents Sign standing authorizations for automatic revenue notifications enabling rapid and increased enrollments in funded studies Obtain agreements for permission-based funded studies starting with pharmas / CROs Create awareness of funded studies among YTC members

Proprietary & Confidential © You Take Control, Inc. Initial Solution Offering Rich e-signing services YTC Electronic services easily integrate into existing divergent systems, without introducing new process steps HIPAA compliant audit history available 24/7 Healthcare authorization forms are converted to electronically-signable forms Provide world-class security Protect Provider’s health IT investment

Proprietary & Confidential © You Take Control, Inc. Competition There is Currently NO Other Comparable Solution for This Market Space – Experts all agree Existing Methods are Antiquated, Costly, Inefficient and Most Importantly; Unacceptable for New Systems Deployment Competition Will Eventually Arrive, the Time is Now to Capture 100% Market Share with a first mover advantage

Proprietary & Confidential © You Take Control, Inc. YTC Strengths World-class Executive Team Strong Presence and Reputation and contacts in Marketplace High Barriers to Entry for Potential Competitors IP Protection Worldwide YTC’s First to Market Advantage World-class secure Solution Feature Rich Ease of Use and Integration World-class Partners

Proprietary & Confidential © You Take Control, Inc. Conclusion - Investment Summary Thousands of Post-marketing Surveillance studies required by FDA (2002, >2,400 studies needed) Recent Congressional mandates for accelerating Post-marketing Surveillance studies also fuel YTC’s business model >$16Bn / yr spent on clinical trials with 25% spent solely on patient recruitment YTC has unique solutions that address each of pharma’s ‘Achilles heels’ which has significant value to pharma so potential revenues to YTC may be measured in $Bn within 5 – 10 years